Search 33,000+ CME courses
Back

Catalyst Medical Education, LLC, AKH Inc., Advancing Knowledge in Healthcare

  • Non-alcoholic Fatty Liver Disease

A New Era in MASH: How Disease-Specific Therapies Are Changing the Game and Best Practices for Clinical Integration

Mitigating disease progression due to metabolic-associated steatotic liver disease (MASLD) and metabolic-associated steatohepatitis (MASH) has been challenging due to a lack of disease-specific therapies. A new era of disease management is here with late-stage development and approval of several agents with novel mechanisms of action. This activity will explore current successes and challenges with real-world use of thyroid hormone receptor- (THR- ) agonists through case-based discussions. Updates on emerging clinical efficacy and safety data of late-stage disease-specific therapies will be examined. Also, the latest advances in noninvasive testing to assess liver disease will be presented to optimize patient screening and identification. Transcripts available in English, French, German, Italian, and Spanish. For additional activities and resources, please visit https://mash-ce.com/.

Credit & MOC Details

Credit information is provided by the course provider. We recommend confirming credit eligibility with the provider or your licensing board before starting the activity.

Credit types

AMA PRA Category 1 Credit™Up to 0.75 credits

MOC types

No MOC

FDA REMS

No

Qualifies for MIPS

No

Target Specialties

Pricing

Free

Reported to ACCME by the provider

  • Case-based learning
  • Credit · Up to 0.75 credits
  • Commercial Support
  • Released
    Oct 20, 2025
  • Last day to claim credit
    Oct 21, 2026 9 days left

Related courses

See all

Other providers’ courses on the same topic

More from AKH Inc., Advancing Knowledge in Healthcare

See all

This provider’s courses closest to this one